Publications by authors named "N Despiegel"
Bone complications (also known as skeletal-related events [SREs]) pose significant health and financial burdens on patients with bone metastases. Denosumab demonstrated superiority over zoledronic acid in delaying the time to first SRE. This study examined the lifetime cost-effectiveness of denosumab vs zoledronic acid from both US payer and societal perspectives.
View Article and Find Full Text PDFIntroduction: New therapies for multiple myeloma (MM) have improved life expectancy, but health-related quality of life (HRQoL) data from patients with MM in the real-world setting are lacking. This study, conducted in France, explored the associations between treatment outcomes and HRQoL in patients with MM.
Patients And Methods: This observational, cross-sectional, multicenter study enrolled patients (≥ 18 years old) with symptomatic MM who had consulted a physician at least once between February and March 2016.
: Automated healthcare databases (AHDB) are an important data source for real life drug and healthcare use. In the filed of depression, lack of detailed clinical data requires the use of binary proxies with important limitations. The study objective was to create a Depressive Health State Index (DHSI) as a continuous health state measure for depressed patients using available data in an AHDB.
View Article and Find Full Text PDFObjectives: To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and INI-naïve HIV-infected adults with at least two classes resistance compared to raltegravir (RAL), by adapting previously published Anti-Retroviral Analysis by Monte Carlo Individual Simulation (ARAMIS) model.
Methods: ARAMIS is a microsimulation Markov model with a lifetime time horizon and a monthly cycle length. Health states are defined as with or without opportunistic infection and death.
Article Synopsis
- The ARAMIS model was used to analyze the cost-effectiveness of dolutegravir (DTG) in Canadian HIV patients, comparing it with several other treatments for both treatment-naive (TN) and treatment-experienced (TE) cases.
- Results showed that DTG was consistently more effective in increasing quality-adjusted life-years and was associated with significant cost savings compared to other treatments.
- The study concluded that DTG is a superior option for managing HIV due to its high efficacy and resistance barrier, making it the preferred choice in both TN and TE patient populations.